

8th February, 2021

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051 (NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2020

The presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2020 to be made to analysts is enclosed for your records.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY

Encl: A/a



Q3 FY 2020-21

Revenues: Summary



Revenue: Summary

Revenues (Rs cr)	Q3 FY21	Q3 FY20	Gr%	9M FY21	9M FY20	Gr%
India	930	871	7%	2,818	2,677	5%
United States	292	381	-24%	992	1,138	-13%
Germany	265	219	21%	772	731	6%
Brazil	173	189	-8%	441	519	-15%
Other countries	191	195	-2%	625	566	10%
Others (Inc. CRAMS)	145	110	32%	421	362	16%
Total	1,995	1,966	2%	6,068	5,993	1%

